The Discounted Cash Flow (DCF) valuation of Supernus Pharmaceuticals Inc (SUPN) is 40.64 USD. With the latest stock price at 32.47 USD, the upside of Supernus Pharmaceuticals Inc based on DCF is 25.2%.
Based on the latest price of 32.47 USD and our DCF valuation, Supernus Pharmaceuticals Inc (SUPN) is a buy. buying SUPN stocks now will result in a potential gain of 25.2%.
| Range | Selected | |
| WACC / Discount Rate | 6.2% - 7.6% | 6.9% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | 27.35 - 89.37 | 40.64 |
| Upside | -15.8% - 175.2% | 25.2% |